Expect Limited Use of IV Brexanolone (Zulresso) for Postpartum Depression
May 2019
Intravenous brexanolone (Zulresso, zul-REH-soh) will make a splash as the first FDA-approved treatment for postpartum depression.
Brexanolone has a unique mechanism...it mimics the hormone allopregnanolone, which interacts with GABA receptors. This hormone abruptly dips around childbirth...possibly leading to major depression.
Brexanolone is given as a single 60-hour infusion. It starts to improve depression symptoms 24 to 48 hours after starting the infusion. In comparison, SSRIs take at least 1 to 2 weeks to start working.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote